Lecia V Sequist
ECOG-ACRIN Cancer Research Group · Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lecia V Sequist as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06303167 · Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
- N/ANCT04614129 · Lung Cancer Risk and Early Detection in FirefightersMassachusetts General Hospital · completed · Lung Cancer, Lung Diseases · principal investigator
- Ph2NCT03778229 · Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibAstraZeneca · active not recruiting · Carcinoma · principal investigator
- Ph2NCT01553942 · Afatinib With CT and RT for EGFR-Mutant NSCLCMassachusetts General Hospital · active not recruiting · Lung Cancer · principal investigator
- Ph2NCT01228435 · IPI-504 in NSCLC Patients With ALK TranslocationsMassachusetts General Hospital · terminated · Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer · principal investigator
- N/ANCT01074177 · Understanding Mechanisms of Acquired Resistance to BIBW2992Massachusetts General Hospital · completed · Non-small Cell Lung Cancer, EGFR Mutations · principal investigator
- N/ANCT01061944 · Biopsies of Cancer Patients for Tumor Molecular CharacterizationMassachusetts General Hospital · completed · Cancer, Metastatic Cancer · principal investigator
- Ph2NCT00567359 · Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFRMassachusetts General Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT00411047 · Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung CancerMassachusetts General Hospital · completed · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical ApplicationsR61CA287026 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2024 to 2026 · $234,218 awarded in 2026Same name and institution; not confirmed by an ID
- Training Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2020 to 2026 · $311,872 awarded in 2026Same name and institution; not confirmed by an ID
- Non-genomic resistance mechanisms in EGFR-mutant lung cancerR01CA137008 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2015 to 2023 · $392,337 awarded in 2023Same name and institution; not confirmed by an ID
- Repeat Biopsies in Lung Cancer to Define Targeted Resistance MechanismsR21CA156000 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2011 to 2012 · $230,985 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT06303167
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:24 UTC. The ranking covers the 200 most relevant of 72 PubMed records, and a shared surname and initials can bring in a namesake. All 72 on PubMed
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med · 20103,653 citationsRCR 86.4
- Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol · 20132,733 citationsRCR 77.3
- 1,447 citationsRCR 39.7
- 1,313 citationsRCR 39.5
- 1,193 citationsRCR 35.0
- 964 citationsRCR 27.6
- 862 citationsRCR 23.0
- First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.J Clin Oncol · 2008699 citationsRCR 14.1
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.J Clin Oncol · 2018609 citationsRCR 18.9
- Rociletinib in EGFR-mutated non-small-cell lung cancer.N Engl J Med · 2015539 citationsRCR 15.6